The results from network pharmacology analysis showed that the PI3K-AKT pathway is one of the targets of ASD to against major depressive disorder (MDD), anxiety and Alzheimer’s disease (AD). This evidence concerns the gene AKT1 and early-onset autosomal dominant Alzheimer disease.